Compare ARQT & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | SAM |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2020 | 1996 |
| Metric | ARQT | SAM |
|---|---|---|
| Price | $23.69 | $176.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 11 |
| Target Price | $34.00 | ★ $233.70 |
| AVG Volume (30 Days) | ★ 1.7M | 273.5K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 88.79 | ★ 95.45 |
| EPS | ★ N/A | N/A |
| Revenue | $376,072,000.00 | ★ $1,964,994,000.00 |
| Revenue This Year | $34.85 | $1.02 |
| Revenue Next Year | $29.39 | $1.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $12.72 | $158.68 |
| 52 Week High | $31.77 | $264.46 |
| Indicator | ARQT | SAM |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | 43.45 |
| Support Level | $22.41 | $169.98 |
| Resistance Level | $23.87 | $228.42 |
| Average True Range (ATR) | 0.85 | 6.89 |
| MACD | 0.34 | 2.00 |
| Stochastic Oscillator | 91.83 | 58.93 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.